Penumbra has introduced Ruby XL System, the detachable embolisation coil, which has also received clearance from the US Food and Drug Administration (FDA).
The system is tailored to aid physicians during embolisation procedures by minimising radiation exposure and enhancing outcomes, particularly in large-vessel and high-flow embolisation.
Related: Avicenna.ai secures CE marks for two AI fracture detection tools
It introduces three technologies: Ruby XL, POD XL, and Packing Coil XL. These can be delivered via a diagnostic catheter.
The coils offer increased volume, up to 40mm in size, and extended lengths of up to 70cm.
The Ruby XL coil is engineered with a complex 3D shape to frame aneurysms across several clinical applications.
With a multistage, hybrid design, POD XL includes anchoring and framing, as well as a dense filling segment, making it ideal for high-flow vessels.
The Packing Coil XL employs a liquid metal wave shape technology, allowing it to dynamically adjust to the size of any vessel, with lengths up to 70cm.
Penumbra Interventional Business president Shruthi Narayan said: “We’ve engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings.
“Ruby XL embodies Penumbra’s commitment to innovation, delivering mechanical occlusion through more volume without sacrificing softness or deliverability.”
The thrombectomy company develops solutions for medical conditions such as ischemic stroke, venous thromboembolism, pulmonary embolism, and acute limb ischemia.
Its portfolio, which includes computer-assisted vacuum thrombectomy (CAVT), is intended to remove blood clots safely.
Last year, the company reported positive data for CAVT technology aimed at treating individuals with intermediate-risk pulmonary embolism.
